← SynDRA
RIOCIGUAT
SynDRA canonical compound SYN0033278 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | GUCY1B1 |
|---|
| Mechanism of action | Guanylate cyclase stimulant |
|---|
| Indication | hypertension |
|---|
| Disease area | cardiology |
|---|
All known targets
- GUCY1B1
- GUCY1A1
- GUCY1A2
- GUCY1B2
- GUCY2D
- PDE7B
Mechanisms of action (all sources)
- Guanylate cyclase stimulant
- GUCY1B1 POSITIVE ALLOSTERIC MODULATOR
- GUCY1A2 POSITIVE ALLOSTERIC MODULATOR
- GUCY1A1 POSITIVE ALLOSTERIC MODULATOR
- GUCY1A1 ACTIVATOR
- GUCY1B1 ACTIVATOR
- GUCY1A2 ACTIVATOR
- GUCY2D MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- KCNH2
- ACHE
- HTR2B
- SLC6A4
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KDR
- HTR1A
- ADORA3
- HRH3
- HDAC6
- F2
- ESR1
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Enzyme Activators
- Guanylate Cyclase Stimulators
- Soluble Guanylate Cyclase Stimulator
ATC classes
- C02K · OTHER ANTIHYPERTENSIVES
Cross-references
Synonyms
- ADEMPAS
- Adempas
- adempas
- BAY 63-2521
- Bay 63-2521
- Riociguat (BAY 63-2521)
- riociguatum
- UNII-RU3FE2Y4XI
- RU3FE2Y4XI
- CHEBI:76018
- BAY-63-2521
- Riociguat [INN]
- Riociguate
- Riociguat [USAN:INN:JAN]
- Riocguat-d3
- Adempas (TN)
- BAY-632521
- RIOCIGUAT [JAN]
- RIOCIGUAT [MI]
- RIOCIGUAT [USAN]
- RIOCIGUAT [VANDF]
- RIOCIGUAT [USP-RS]
- RIOCIGUAT [WHO-DD]
- Bay 63-2521,Riociguat
- Riociguat (JAN/USAN/INN)
- SCHEMBL245457
- GTPL5257
- RIOCIGUAT [ORANGE BOOK]
- CHEMBL2107834
- RIOCIGUAT [EP MONOGRAPH]
- AMY4218
- DTXSID50978109
- RIOCIGUAT [USP MONOGRAPH]
- BCP04750
- BCP23980
- EX-A2023
- ZINC3819392
Reported adverse events
- Constipation
- Dizziness
- Dyspepsia
- Gastritis
- Headache
- Hypotension
- Nausea
- Vomiting
Look up RIOCIGUAT in the interactive SynDRA portal →